Actively Recruiting
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants
Led by Jiangsu Province Centers for Disease Control and Prevention · Updated on 2024-09-20
785
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to evaluate immune persistence at 30 and 36 Months of Age and Pertussis Breakthrough Infections between 19 and 36 Months of Age following two regiments of DTaP-IPV/Hib Pentavalent Vaccine in Healthy 2-Month-Old Infants and Children in China.
CONDITIONS
Official Title
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Received 4 doses of DTaP-IPV/Hib pentavalent vaccines
- Obtained consent from the participant's caregiver and signed an informed consent form
You will not qualify if you...
- Diagnosed by a physician with a coagulation abnormality such as coagulation factor deficiency, coagulopathy, or platelet abnormality
- Any other factor considered to make participation in the trial unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jingsu Provincial Centre of Disease Control and Prevention
Nanjing, Jiangsu, China, 210009
Actively Recruiting
Research Team
J
Jingxin Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here